CN104983733B - Application of the Nicardipine in preparation anti-lung cancer product - Google Patents
Application of the Nicardipine in preparation anti-lung cancer product Download PDFInfo
- Publication number
- CN104983733B CN104983733B CN201510385948.8A CN201510385948A CN104983733B CN 104983733 B CN104983733 B CN 104983733B CN 201510385948 A CN201510385948 A CN 201510385948A CN 104983733 B CN104983733 B CN 104983733B
- Authority
- CN
- China
- Prior art keywords
- nicardipine
- lung cancer
- drug
- cell
- nci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of the Nicardipine in preparation anti-lung cancer product.The present invention provides application of the Nicardipine in preparation treatment non-small cell lung cancer product.The experiment proves that, the present invention is to FDA, CFDA granted drug Nicardipine carries out tumour medicine reorientation, it is not that anti-tumor drug is screened to indication according to the different cell line of tumour (organization type) and mutational site, it was found that Nicardipine anti-small cell lung carcinoma and/or this new application of non-small cell lung cancer, realize that old medicine is newly used.
Description
Technical field
The answering in preparation anti-lung cancer product the present invention relates to field of biotechnology more particularly to a kind of Nicardipine
With.
Background technique
Tumour be threaten human health it is most common be also most serious a kind of disease, research and development high efficiency anti-tumor drug is to prolonging
The life cycle of long patient is most important.In recent years, novel with the rapid development of cancer genomics and molecular pharmacology
The research and development of anti-tumor drug achieve good achievement, but since new drug development investment is big, the bottlenecks such as period length can not overcome, with
And the features such as tumour individual inheritance variation is big, cause many traditional anti-tumor drug effects to be not added, new drug is expensive, side effect
It is unknown.
The researchers such as Barabasi AL were published in the paper middle finger of " Nature Reviews Genetics " in 2011
Out, the molecular network analysis carried out based on GWAS result of study and interaction group (interactome) strategy is expected to disclose complicated
Disease new drug target and molecular marker, and ultimately form the understanding completely new to disease incidence mechanism and therapeutic scheme.More
It is worth noting that, drug reorientation (drug repositioning) the study found that GWAS research locking tumor susceptibility gene and
There is the gene of protein-protein interaction (protein-protein interaction, PPI) to be easier to become drug with it
Indirect target spot, this discovery help to explain the research and development that the mechanism of action of existing drug and guides new drug.2014, Okada
The rheumatoid arthritis that GWAS result of study confluence analysis obtains is shown in the paper that the researchers such as Y deliver on " Nature "
101 tumor susceptibility genes in have 98 at present be used for treatment medicine for treating rheumatoid arthritis direct or indirect targets, and
It is also relocated and is studied by drug, they are also found the granted drug for other indications of dozens of and can also be used for controlling
Treat rheumatoid arthritis.
Summary of the invention
This research is exactly based on the cancer gene spectrum Cancer for integrating cancer group Cosmic version72 database
Gene Census and protein interaction 10 database of STRING version and DrugBankversion4.2 in FDA
The drug data base of approval, the candidate reorientation drug of acquisition, carries out screening experiment to tumor cell line, filters out new resisting and swells
Tumor medicine.Do tumor cell line screening candidate tumor inhibit drug see it is as follows:
Nicardipine,Promethazine,Estrone,Nicardipine,Sunlidac,Nicardipine,
Etonogestrel,Levonorgestrel,Mesalazine,Indomethacin,Sulfasalazine,
Balsalazide,Irbesartan,Ibuprofen,Isoprenaline,Pentosan Polysulfate。
It is an object of the present invention to provide the new applications of Nicardipine.
Application of the Nicardipine provided by the invention in preparation treatment lung cancer product.
A second object of the present invention is to provide the new applications of Nicardipine.
The present invention provides Nicardipine to inhibit the application in proliferation of lung cancer cells product in preparation.
Third object of the present invention is to provide the new applications of Nicardipine.
The present invention provides Nicardipine to reduce the application in lung carcinoma cell IC50 value product in preparation.
In above-mentioned application, the lung carcinoma cell is Small Cell Lung Cancer or non-small cell lung cancer；The lung carcinoma cell is small thin
Born of the same parents' lung carcinoma cell or non-small cell lung cancer cell；The non-small cell lung cancer cell is specially NCI-H524；The cellule lung
Cancer cell is specially NCI-H446.
In above-mentioned application, the product is drug or kit.
Fourth object of the present invention is to provide a kind of product.
Product provided by the invention, active constituent Nicardipine；The product has following at least one function
Can:
1) lung cancer is treated；
2) inhibit proliferation of lung cancer cells；
3) lung carcinoma cell IC50 value is reduced.
In the said goods, the lung carcinoma cell is Small Cell Lung Cancer or non-small cell lung cancer；The lung carcinoma cell is small thin
Born of the same parents' lung carcinoma cell or non-small cell lung cancer cell；The non-small cell lung cancer cell is specially NCI-H524；The cellule lung
Cancer cell is specially NCI-H446.
In the said goods, the product is drug or kit.
The experiment proves that the present invention carries out tumour medicine to FDA, CFDA granted drug Nicardipine
Object reorientation, according to the different cell line of tumour (organization type) and mutational site be not anti-tumor drug to indication into
Row screening, finds Nicardipine anti-small cell lung carcinoma and/or this new application of non-small cell lung cancer, realizes that old medicine is newly used.
Detailed description of the invention
Fig. 1 is that 96 well culture plate medicines sieve the distribution of drug template.
Fig. 2 is that Nicardipine is sensitive to non-small cell lung cancer；EC50=20.2548；IC50=18.5548；R2=
0.9866。
Fig. 3 is that Nicardipine is sensitive to Small Cell Lung Cancer；EC50=18.0489；IC50=18.4046；R2=
0.9998。
Specific embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
Drug to be measured is Nicardipine in following embodiments, and chemical structural formula is as follows:
It is drug bank product, and catalog number is
DB00622(APRD00088)。
Non-small cell lung carcinoma cell NCI-H524 and human small cell lung carcinoma cell NCI-H446, people in following example
The source of liver cancer cells SNU-449 and human lung carcinoma cell NCI-H810 are as follows:
NCI-H524 ATCC CRL-5831
NCI-H446 ATCC HTB-171
SNU-449 ATCC CRL-2234
NCI-H810 ATCC CRL-5816
Main instrument and consumptive material in following example
DMSO(from Sigma,Cat.No.D4540)
The saturating tissue culture plate of 96-well white bottom (from Corning, Cat.No.3610)
CellTiter Glo kit (from Promega, Cat.No.G7573)
Doxorubicin positive drug (from MCE, Cat.No.HY-15142)
Fetal Bovine Serum(from Gibco,Cat# 10099141)
100mm culture dish (from Corning, Cat# 430167)
RPMI-1640 medium(from Gibco,Cat# A1049101)
DMEM medium(from Gibco,Cat# 11995081)
DMEM/F12 medium(from Gibco,Cat# 11330057)
EMEM medium(from Gibco,Cat# 10370021)
384 cell dispenser (Thermo, Cat# 5840150) of Mutidrop
The multi-functional plate reading machine of EnSpire (Perkin Elmer, Cat# 2300-001M)
Embodiment 1, CELLTITER-GLO detect the anti-non-small cell lung cancer of Nicardipine
One, the preparation of orifice plate to be measured
1, plating cells
A) complete medium needed for preparing each cell
B) experiment start before, medicine sieve cell name of the confirmation flag on 100mm culture dish, culture medium and passage when
Between, the information such as generation, it is ensured that experiment is errorless.
C) attached cell operation is with reference to step d) to i), and suspension cell operation is with reference to step j) to l).
D) cell culture medium is drawn using vacuum pump when sterile working.
E) the sterile PBS solution rinse cell surface of 2ml is used, then PBS waste liquid is pumped out with vacuum.
F) it is thin that 1ml 0.25% (w/v) Trypsin-0.038% (w/v) EDTA solution digestion is gently added to culture dish
Born of the same parents, mix gently it is several under, solution covers cell surface, under inverted microscope observe cell dissociation situation, cell will
Pancreatin digestion is terminated when falling off.
G) 37 DEG C of preheated complete mediums of 5ml are added into culture dish, gently blows and beats cell with pipette, makes it
It is split away off from culture dish bottom.
H) this cell suspension is transferred in 15ml or 50ml sterile centrifugation tube, 1000rpm is centrifuged 5min.
I) supernatant culture medium is sucked out using vacuum pump sterile working.37 DEG C of 5ml preheated complete mediums are added to be resuspended
Cell precipitation, gently piping and druming mixes.
J) cell is gently blown and beaten with pipette, it is made to completely fall off from culture dish bottom.
K) this cell suspension is transferred in 15ml or 50ml sterile centrifugation tube, 1000rpm is centrifuged 5min.
L) supernatant culture medium is sucked out using vacuum pump sterile working.37 DEG C of 5ml preheated complete mediums are added to be resuspended
Cell precipitation, gently piping and druming mixes.
M) cell suspension is counted with cell counter, adjustment cell suspension to proper density fishplate bar carries out cell paving
Plate experiment.
N) NCI-H524 cell and NCI-H446 cell are carried out according to the method described above, respectively obtains 96 hole NCI-H524
Tissue culture plate and NCI-H44696 porocyte culture plates.
NCI-H524 cell, complete medium RPMI-1640 are life product, A1049101, fishplate bar density
It (cells/well) is 16000.
NCI-H446 cell, complete medium RPMI-1640 are life product, A1049101, fishplate bar density
It (cells/well) is 8000.
2, drug Nicardipine preparation and dosing (200X final concentration) to be measured:
1) drug Nicardipine motherboard to be measured is prepared
A) that drug Nicardipine to be measured is diluted to 20mM with DMSO is stand-by.
B) it takes configured 20mM 79 μ L of drug to be measured in a) step to be added in dilution the first hole of plate the first row, is then added
The DMSO solvent of 54 μ L to the second hole of the first row into the 9th hole, from taking 25 μ L solution in the first hole into the second hole, after mixing
From taken in the second hole 25 μ L solution into third hole, and so on to the 9th hole, guarantee that drug gradually carries out 3.16 times of multiple proportions ladders
Degree dilution.
2) positive drug Doxorubicin (MCE, Cat.No.HY-15142) motherboard is prepared
A) that positive drug Doxorubicin is diluted to 6mM with DMSO is stand-by.
B) 6mM positive drug Doxorubicin solution is added in dilution plate, 1:3.16 times of multiple proportions gradient dilution of DMSO solution
The drug to be measured.
3, the preparation of drug working plate and dosing
A) drug to be measured and positive drug sample-adding template are as shown in Figure 1, wherein and S1208: positive drug Doxorubicin,
DMSO: Positive control wells, Cpd 1,2,3: drug to be measured, DMSO final concentration of 0.5% (DMSO compatibility).
B) the 95 specific complete mediums of μ l cell, corresponding 9 holes of each drug, with the multiple tracks volley of rifle fire are added into working plate
Successively shift a series of good molten of (9 holes) doubling dilutions of 5 μ l respectively from drug to be measured and positive drug doxorubicin motherboard
Liquid (10X final concentration), obtains the cell culture medium containing various concentration drug.
C) step 1 preparation 96 porocyte culture plates of NCI-H524 and the training of the hole NCI-H44696 cell are taken out from incubator
Plate is supported, it is thin to 96 porocyte culture plates of NCI-H524 and the hole NCI-H44696 respectively by Fig. 1 dosing template arrangement mode (Fig. 1)
The cell culture medium (10X final concentration) containing various concentration drug of the above-mentioned b) preparation of 10 μ l is added in born of the same parents' culture plate, is put into
CO237 DEG C of culture 72h of incubator, obtain the 96 hole medicine sieve plates of NCI-H524 and the 96 hole medicine sieve plates of NCI-H446.
Using be not added any drug as control wells.
The final concentration and dosing situation of above-mentioned drug to be measured, positive drug Doxorubicin and control wells in 96 orifice plates are such as
Under:
Final concentration (μM) of the drug to be measured in the hole 2-10 of Fig. 1 is successively are as follows: 100,31.64557,10.01442,
3.16912,1.002886,0.317369,0.100433,0.031783,0.010058；
Final concentration (μM) of the positive drug Doxorubicin in the hole 2-10 of Fig. 1 is successively are as follows: 30,9.493671,
3.004326,0.950736,0.300866,0.095211,0.03013,0.009535,0.003017；
In addition, the hole S1208 (E1-H1 and A12-D12): 10 100 μM of Doxorubicin solution of μ l final concentration in 96 orifice plates
(solvent be the complete medium solution comprising 0.5%DMSO), the hole DMSO (A1-D1, E12-H12 and A11-H11): 10 μ l include
The complete medium solution of 0.5%DMSO.
Two, CELLTITER-GLO fluorecyte activity monitor system detects
1, CellTiter-Glo preparation of reagents
A) before use, CellTiter-Glo reagent Buffer is melted, room temperature use is equilibrated to.
B) before use, CellTiter-Glo reagent agar substrate is melted, room temperature use is equilibrated to.
C) the CellTiter-Glo Buffer for taking 100ml to balance is added to bottled CellTiter-Glo reagent agar
In substrate, it is resuspended sufficiently and forms enzyme/substrate mixture, that is, so-called CellTiter-Glo detection reagent.
D) vortex is mixed gently, and is inverted repeatedly and obtains uniform solution.In general, CellTiter-Glo in 1 minute
Substrate reagent will sufficiently dissolve, and packing is kept in dark place spare at -20 DEG C, avoids multigelation.
2, it detects
A) before detecting, 96 hole medicine sieve plates for the NCI-H524 that the 3 of above-mentioned one are obtained and the 96 hole medicine sieve plates of NCI-H446
It balances 20-30 minutes at room temperature.
B) inverted microscope observes the cellular morphology and death condition of every piece of culture plate, marks abnormal conditions and repetition measurement one
It is secondary.
C) the CellTiter-Glo reagent of above-mentioned 1 preparation of 100 μ l is added into all medicine sieve pores, mixes.
D) mixing 2 minutes fullys shake in 96 hole microplate oscillators, cracks cell completely.
E) it is protected from light progress luminescence signal detection after being placed at room temperature for 15 minutes, guarantees the stability of signal.
F) luminescence signal is read when plate reading machine 570nm multi-functional using EnSpire.
G) analyzing and processing data.
The 96 hole medicine sieve plate results of NCI-H524 are as shown in Figure 2.
The 96 hole medicine sieve plate results of NCI-H446 are as shown in Figure 3.
IC50 value is calculated, the results are shown in Table 1.
Human liver cancer cell SNU-449 and human lung carcinoma cell NCI- is acted on using same method detection Nicardipine
The IC50 value of H810, as a result such as table 1.
As can be seen that Nicardipine has Specific Inhibitory Effect to cell proliferation of NSCLC, can be used to make
For the drug for treating non-small cell lung cancer.
Table 1 is IC50 value of the different cells under Nicardipine drug effect
| Cell | IC50 value |
| NCI-H446 | 18.40459175 |
| SNU-449 | 100 |
| NCI-H524 | 18.55482631 |
| NCI-H810 | 100 |
Claims (3)
- Application of the 1.Nicardipine in preparation treatment lung cancer product；The lung cancer is Small Cell Lung Cancer.
- 2.Nicardipine inhibits the application in proliferation of lung cancer cells product in preparation；The lung carcinoma cell is Small Cell Lung Cancer Cell；The small cell lung cancer cell is specially NCI-H446.
- 3. application according to claim 1 or 2, it is characterised in that: the product is drug or kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510385948.8A CN104983733B (en) | 2015-06-30 | 2015-06-30 | Application of the Nicardipine in preparation anti-lung cancer product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510385948.8A CN104983733B (en) | 2015-06-30 | 2015-06-30 | Application of the Nicardipine in preparation anti-lung cancer product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104983733A CN104983733A (en) | 2015-10-21 |
| CN104983733B true CN104983733B (en) | 2019-01-08 |
Family
ID=54295724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510385948.8A Active CN104983733B (en) | 2015-06-30 | 2015-06-30 | Application of the Nicardipine in preparation anti-lung cancer product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983733B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648764A4 (en) * | 2017-07-03 | 2021-03-31 | Menri Group Ltd. | Treatment of cancer with dihydropyridines |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406473A (en) * | 2007-10-12 | 2009-04-15 | 中国科学院上海有机化学研究所 | Use of dihydropyrimidine compound and pharmaceutical composition containing the same |
| US20100168186A1 (en) * | 2006-04-18 | 2010-07-01 | Ekr Therapeutics, Inc. | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060009506A1 (en) * | 2004-07-09 | 2006-01-12 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
| CN101869708A (en) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
-
2015
- 2015-06-30 CN CN201510385948.8A patent/CN104983733B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100168186A1 (en) * | 2006-04-18 | 2010-07-01 | Ekr Therapeutics, Inc. | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions |
| US20110152327A1 (en) * | 2006-04-18 | 2011-06-23 | Ekr Therapeutics, Inc. | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions |
| CN101406473A (en) * | 2007-10-12 | 2009-04-15 | 中国科学院上海有机化学研究所 | Use of dihydropyrimidine compound and pharmaceutical composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104983733A (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104983733B (en) | Application of the Nicardipine in preparation anti-lung cancer product | |
| Gordon et al. | Evaluating whole-genome expression differences in idiopathic and diabetic adhesive capsulitis | |
| CN105012314B (en) | Applications of the Etonogestrel in anti-prostate cancer product is prepared | |
| CN105030792B (en) | Applications of the Desogestrel in the positive breast cancer product of the negative AhRs of inhibitor against colon carcinoma cells/ER is prepared | |
| CN105816467B (en) | Etonogestrel is preparing the application in anti-B cell lymphoma product | |
| US20220152046A1 (en) | Applications for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products | |
| CN104983735B (en) | Applications of the Estrone in preparing ovarian cancer resistance and/or breast cancer product | |
| CN104983734B (en) | Applications of the Estradiol in anti-small cell lung carcinoma and/or oophoroma and/or osteosarcoma product is prepared | |
| CN105030785B (en) | Applications of the Promethazine in anti-liver cancer and anti-and/or colon cancer and/or lung cancer product is prepared | |
| CN104983736A (en) | Application of Levonorgestrel in preparation of ovarian cancer resistant product | |
| WO2017000083A1 (en) | Applications of nicardipine in preparation of products for resisting against lung cancer | |
| CN105012284A (en) | Application of Sulindac in the preparation of anti-lung cancer products | |
| US10653705B2 (en) | Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products | |
| US11452730B2 (en) | Applications of desogestrel in the preparation of breast cancer ER-negative Ah receptor-positive products | |
| US20220062292A1 (en) | Applications for promethazine in preparing anti-liver cancer and/or colon cancer and/or lung cancer products | |
| US11903914B2 (en) | Applications for sulindac in preparing anti-lung cancer products | |
| US10441591B2 (en) | Applications for etonogestrel in preparing anti-prostate cancer products | |
| Verma et al. | ALK and ERBB2 Protein Inhibition is Involved in the Prevention of Lung Cancer Development by Vincamine | |
| Li et al. | Pan-cancer analysis of the PDE4DIP gene with potential prognostic and immunotherapeutic values in multiple cancers including acute myeloid leukemia | |
| US10792291B2 (en) | Applications for levonorgestrel in preparing anti-ovarian cancer products | |
| Sherlach et al. | Determination of the cytostatic and cytocidal activities of antimalarial compounds and their combination interactions | |
| Chee et al. | RNA Sequencing and Bioinformatics Analysis Reveals the Downregulation of DNA Replication Genes by Morindone in Colorectal Cancer Cells | |
| Elsayed et al. | MALARIA and BURKITT′ S LYMPHOMA: An IN SILICO ANALYSIS of GENE EXPRESSION LINKS BETWEEN MALARIA and BURKITT’S LYMPHOMA and POTENTIAL ANTICANCER ACTIVITY of ARTEMISININ DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |